How we help our clients
Nick Bennett, Director of Research
Identifying issues and opportunities in disease treatment
From our research
-
Crohn's disease: mapping future treatment scenariosPremium
Includes the latest research from ECCO 2011. Understand the treatment landscape for Crohn's disease, including our visual Treatment Map, product opportunities and future market scenarios. Learn about the most significant treatment challenges faced by physicians, including:
- Choosing between traditional immunomodulators, biologics or combined therapies
- Deciding the optimal duration of treatment in patients that respond well to anti-TNF monotherapy
-
SUCCESS-ful New Evidence Impacts Ulcerative Colitis AlgorithmFree
New data was presented at ECCO’s 6th Annual Congress from the SUCCESS trial studying the use of infliximab, azathioprine, and infliximab & azathioprine combination in moderate-to-severe ulcerative colitis.
- Data showed infliximab + azathioprine combination to be significantly superior to both monotherapy arms in inducing steroid-free remission
- Doctors expect the results of SUCCESS to have as significant an impact on ulcerative colitis treatment as SONIC trial data has had on Crohn’s disease
-
Infliximab: New Standard for Severe Refractory Ulcerative ColitisFree
Evidence released at ECCO 2011 from a trial studying the use of ciclosporin vs. infliximab in severe refractory ulcerative colitis will significantly impact current treatment practices.
- Data showed infliximab to be non-inferior to ciclosporin with similar response rates and time to colectomy observed for both groups
- Consensus view is that infliximab should now be considered the standard treatment for severe refractory ulcerative colitis
-
Primary research following ACR 2011Free
Our analysts recently attended the ACR 2011 Scientific Meeting in Chicago. We summarized the key papers in our blog and have selected the topics most significant for clinical practice to discuss with our panel of KOLs in our next round of primary research. These include:
- New oral inhibitors: tofacitinib, fostamatinib and VX-509
- Changing approaches to early, aggressive therapy in RA
- New biologic therapies: latest evidence relating to canakinumab, sarilumab and LY-2439821.
Our Product and Services
Home Page Product & Servces Block text
Published 16/02/2011
Research Reports
Available individually or as part of a series, our premium reports help you understand the treatment landscape.
We highlight the treatment challenges that physicians face and explore commercial opportunities and future scenarios for the pharmaceutical industry.
Treatment Pulse
Treatment Pulse is our online business intelligence service that provides strategic and tactical support by tracking new medical evidence, analyzing its impact on clinical practice through primary research with key opinion-leading doctors and providing in-depth analysis for our clients.